Sanofi opens $77M R&D Fa­cil­ity in Chengdu

BioSpectrum (Asia) - - Company News -

Sanofi has launched a $77 mil­lion Global R&D Op­er­a­tions Hub in Chengdu, which will fo­cus on dig­i­tal­iza­tion and big data anal­y­sis for clin­i­cal tri­als. The China R&D cen­tre will be the third pil­lar of Sanofi Global Clin­i­cal Sci­ences and Op­er­a­tions, join­ing fa­cil­i­ties in France and the United States. The Hub will sup­port clin­i­cal R&D of Sanofi’s in­no­va­tive drugs, managing global multi-cen­ter clin­i­cal tri­als data and files. The new hub plans to re­cruit 300 pharma R&D staff by 2020. Sanofi al­ready has an R&D cen­tre in Shang­hai fo­cus­ing on find­ing drug tar­gets and con­duct­ing tri­als in com­mon dis­eases such as liver dis­eases, di­a­betes, can­cers, and car­dio­vas­cu­lar dis­eases, in the China and Asia-Pa­cific re­gion. Di­a­betes drugs have long been a lynch­pin of Sanofi’s busi­ness, and its ma­jor ri­val in this mar­ket, Novo Nordisk has also in­vested in R&D in China.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.